Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccines

Miriam Sturkenboom(University Medical Center Utrecht), Vincent Bauchau(UCB Pharma (Belgium)), Susan Hahné(National Institute for Public Health and the Environment), M Kokki(European Centre for Disease Prevention and Control), Heidi J. Larson(Institute for Health Metrics and Evaluation), Priya Bahri(European Medicines Agency), Patrick Mahy(Sciensano (Belgium)), Lina Titievsky(Pfizer (United States)), Tyra Grove Krause(Statens Serum Institut), Xavier Kurz(European Medicines Agency), A Chiucchiuini(University of London), Piotr Kramarz(European Centre for Disease Prevention and Control), Simon de Lusignan(University of Oxford), Alena Khromava(Sanofi (Canada)), Laurence Torcel‐Pagnon(Sanofi (France))
Vaccine
November 2, 2019
10.1016/j.vaccine.2019.07.081
Cited by 26

Related Papers

Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
|The Lancet|2016|7.8k
Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015
|The Lancet|2016|6.7k
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015
|JAMA Oncology|2016|6.3k
The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level
|JAMA Oncology|2017|2k
Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
|The Lancet|2016|1.2k